Operating cash flow of just $2.6M in 3Q26 against $39.4M of net income gives an OCF/NI ratio of 0.07, and free cash flow turned deeply negative at -$124.4M in 2Q26, indicating weak cash conversion.
Xencor, Inc. (XNCR) cash flow statement — 15-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Cash from Operations | -172.35M | -135.12M | -202.19M | -77.93M | 24.48M | -16.85M | -5M | 64.37M | -79.76M | -33.68M | 94.62M | 26.67M | -21.35M | -5.45M | -11.05M | -1.08M |
| Operating CF Margin % | - | -107.6% | -182.99% | -44.63% | 14.88% | -6.13% | -4.08% | 41.08% | -196.43% | -94.32% | 108.11% | 96.05% | -224.28% | -53.61% | -116.04% | -15.84% |
| Operating CF Growth % | -254.45% | 33.17% | -159.46% | -418.26% | 245.29% | -236.79% | -107.77% | 180.71% | -136.78% | -135.6% | 254.82% | 224.89% | -291.55% | 50.66% | -918.62% | - |
| Net Income | -117.86M | -91.92M | -236.54M | -133.13M | -55.18M | 82.63M | -69.33M | 26.88M | -70.41M | -48.92M | 23.63M | -17.59M | -16.42M | -60.26M | -8.59M | -11.2M |
| Depreciation & Amortization | 9.82M | 10.51M | 12.11M | 11.5M | 8.8M | 7.49M | 5.79M | 4.3M | 3.25M | 2.03M | 1.47M | 1.11M | 882K | 711K | 527K | 607K |
| Stock-Based Compensation | 38.37M | 43.23M | 53.28M | 0 | 48.91M | 36.98M | 31.62M | 31.85M | 20.55M | 13.65M | 7.85M | 4.87M | 1.86M | 198K | 29K | -57K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -18.97M | 0 | 0 | 0 | 0 | 65K | 0 | 0 | 189K | 302K | 1.1M |
| Other Non-Cash Items | -148.36M | -144.38M | 9.36M | 24.58M | -26.91M | -22.38M | -21.26M | -4.09M | 21K | 3.32M | 2.32M | 1.38M | 507K | 49.77M | 1.7M | 1.85M |
| Working Capital Changes | -46.46M | 47.45M | -40.4M | 19.13M | 48.87M | -102.6M | 48.18M | 5.44M | -33.17M | -3.76M | 59.29M | 36.9M | -8.18M | 3.94M | -5.02M | 6.62M |
| Change in Receivables | -55.54M | 28.73M | -32.67M | 19.83M | 36.86M | -54.94M | -185K | -11M | -9.04M | 7.47M | -8.57M | 2.92M | -2.91M | 293K | -325K | -29K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 1.4M | 0 | 0 | -1.36M | -5.64M | 828K | -541K | 786K | 224K | 370K | 130K |
| Change in Payables | -2.72M | -3.95M | 2.85M | 3.83M | -3.91M | 5.05M | -1.24M | 6.39M | -3.07M | 2.99M | -2.52M | 4.71M | -943K | 1.32M | -522K | -239K |
| Cash from Investing | 190.3M | 139.99M | -7.87M | -110.56M | -119.72M | -46.25M | 100.19M | -50.97M | -164.77M | 31.95M | -213.65M | -185.11M | -2.28M | -1.28M | -1.16M | -1.29M |
| Capital Expenditures | -4.09M | -3.15M | -6.1M | -21.25M | -38.49M | -15.98M | -10.54M | -7.35M | -9.15M | -7.28M | -3.01M | -3.67M | -2.29M | -1.29M | -1.26M | -1.42M |
| CapEx % of Revenue | 2.04% | 2.51% | 5.52% | 12.17% | 23.39% | 5.81% | 8.59% | 4.69% | 22.53% | 20.38% | 3.44% | 13.24% | 24% | 12.72% | 13.21% | 20.72% |
| Acquisitions | 1.73M | 0 | 0 | 501K | 0 | -2.66M | 0 | 0 | -1.93M | -33.92M | 920K | -1.75M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 7.69M | 14.39M | -3.38M | 0 | 90K | -3.16M | -3.23M | -3.69M | 2.02M | 33.92M | -920K | 1.75M | 2K | 16K | 97K | 133K |
| Cash from Financing | 18.29M | 8.23M | 197.15M | 188.72M | 5.7M | 43.04M | 18.04M | 10.66M | 254.24M | 3.73M | 120.97M | 116.38M | 308K | 82.39M | -12K | -11K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8K | -10K | -12K | -11K |
| Equity Issued (Net) | 18.29M | 9.96M | 201.26M | 5.39M | 0 | 28.92M | 0 | 0 | 260.25M | 0 | 126.55M | 122.91M | 0 | 90.52M | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -1.73M | -4.1M | 183.33M | 5.7M | 14.12M | 18.04M | 10.66M | -6M | 3.73M | -5.57M | -6.53M | 316K | -8.11M | 0 | 0 |
| Net Change in Cash | 36.24M | 13.1M | -12.91M | -152K | -89.54M | -20.06M | 113.23M | 24.07M | 9.72M | 2M | 1.94M | -42.06M | -23.33M | 75.66M | -12.22M | -2.38M |
| Free Cash Flow | -176.45M | -138.27M | -208.28M | -96.37M | -18.92M | -32.83M | -18.77M | 53.34M | -88.9M | -40.96M | 91.61M | 22.99M | -23.64M | -6.75M | -12.31M | -2.5M |
| FCF Margin % | -88.01% | -110.11% | -188.51% | -55.19% | -11.5% | -11.93% | -15.3% | 34.04% | -218.96% | -114.7% | 104.67% | 82.81% | -248.28% | -66.33% | -129.25% | -36.56% |
| FCF Growth % | -22.81% | 33.62% | -116.12% | -409.4% | 42.38% | -74.91% | -135.2% | 159.99% | -117.04% | -144.71% | 298.45% | 197.27% | -250.32% | 45.19% | -391.61% | - |
| FCF per Share | -2.25 | -1.86 | -3.20 | -1.59 | -0.32 | -0.54 | -0.33 | 0.91 | -1.65 | -0.87 | 2.16 | 0.59 | -0.75 | -0.22 | -0.74 | -0.15 |
| FCF Conversion (FCF/Net Income) | 1.50x | 1.47x | 0.87x | 0.59x | -0.44x | -0.20x | 0.07x | 2.40x | 1.13x | 0.69x | 4.00x | -1.52x | 1.30x | 0.09x | 1.29x | 0.10x |
| Interest Paid | 5K | 0 | 33K | 0 | 13K | 0 | 15K | 11K | 16K | 13K | 21K | 13K | 9K | 0 | 0 | 0 |
| Taxes Paid | 4.13M | 0 | 6.1M | 0 | 700K | 0 | 0 | 400K | 233K | 969K | 936K | 1K | 1K | 0 | 0 | 0 |
Quick answers to the most common questions about buying XNCR stock.
Xencor, Inc. (XNCR) generated $-135.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Xencor, Inc. (XNCR) reported negative free cash flow of $138.3M in 2025, indicating capital requirements exceeded cash from operations.
Xencor, Inc. (XNCR) spent $3.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Net Income Diverges From Operating Cash
Based on reported figures, Xencor's 3Q26 net income of $39.4M sits against operating cash flow of just $2.6M, an OCF/NI ratio of 0.07 that suggests the reported profit was largely non-cash or non-operating in nature.
The gap between net income and operating cash flow is the central signal in this dataset, since most other quarters show net losses paired with heavy operating cash outflows that are larger in magnitude. The single profitable quarter appears driven by items outside core collaboration cash generation, which warrants investigation of the underlying accounting entries before treating it as an earnings inflection. Investors should monitor whether future profitable quarters convert to positive operating cash flow, as the current data does not yet establish earnings quality.
Free Cash Flow Remains Episodically Negative
According to the reported quarterly series, free cash flow turned negative in most periods, reaching -$124.4M in 2Q26 and -$68.2M in 1Q26, with only the 3Q26 quarter delivering a marginal positive figure of $838K.
Free cash flow margins swing sharply, from -15.1% in 1Q26 to -2.4% in 2Q26 and only 0.7% in 3Q26, which reflects the lumpy timing of collaboration receipts rather than a steady operating trend. The 2Q26 burn of $124.4M against much smaller prior-year quarters suggests cash consumption has accelerated, and the single positive quarter does not yet establish durable self-funding capacity. Based on these figures, the company appears dependent on episodic partner payments to offset ongoing development spending.
Minimal Capital Intensity Reflects Asset-Light Model
Reported capital expenditures ran between $183K and $3.0M per quarter across the series, equating to a CapEx-to-revenue ratio that spiked to 17.8% in 2Q24 but has otherwise remained low single digits.
The model is structurally asset-light, consistent with a licensing and clinical-development business that outsources manufacturing and does not require heavy fixed investment. The spike in 2Q24 is an outlier relative to the broader pattern and may reflect a one-time facility or equipment outlay rather than a recurring requirement. Because maintenance capital needs appear modest, the cash burn is driven almost entirely by operating and R&D spending rather than by reinvestment in physical assets.
Working Capital Swings Amplify Quarterly Volatility
As reported in the cash flow statements, working capital changes ranged from -$28.8M in 3Q26 to +$25.3M in 1Q25, a swing large enough to materially distort quarterly operating cash flow relative to underlying performance.
The magnitude of working capital movements relative to operating cash flow indicates that timing of deferred revenue recognition and receivable collection drives much of the reported quarterly variance. Large negative working capital draws in recent quarters coincide with the deepest operating cash outflows, suggesting partner payment timing is a meaningful source of volatility. Investors should treat single-quarter operating cash flow with caution and focus on trailing averages that smooth these timing effects.
Cumulative Cash Outflows Outweigh Reported Earnings
Across the ten reported quarters, cumulative operating cash flow is deeply negative, with the bulk of the outflow concentrated in 2Q26 at -$123.3M and 1Q26 at -$67.6M, a pattern that contrasts sharply with the single profitable quarter.
Summing the available periods, the company has consumed substantially more operating cash than the net income figures alone would imply, indicating that reported losses understate the true cash drain in several quarters. The divergence is most pronounced in recent periods, where net losses and operating outflows both widened. This pattern appears inconsistent with a self-sustaining royalty model and may indicate continued reliance on external capital or partner upfronts to fund development.
What the Cash Statement Leaves Unexplained
Reported stock-based compensation of $9.4M to $18.8M per quarter is a non-cash add-back that flatters operating cash flow comparisons, and the data does not disclose the composition of the 3Q26 profit or the timing of pending partner payments.
Stock-based compensation is excluded from cash burn in the reported operating line, so a portion of the economic cost of the R&D organization is paid in equity rather than cash, which may understate dilution pressure for shareholders. The data also does not isolate the drivers behind the 3Q26 net income, leaving open whether it reflects a non-recurring milestone or a classification effect that would not repeat. Investors should monitor future filings for disclosure of the nature of these gains and for any financing activity that could indicate the current cash position does not cover the development plan.